Several mechanisms of the anti-tumor activity of CB2 agonists have been reported, including PI3K/AKT inhibition [25], modification of metalloproteinases [21], induction of reactive oxygen species [26], MAPK modulation [20] and so on. This evidence concerns the gene CNR2 and neoplasm.